Research output: Contribution to journal › Article › peer-review
Experimental infection using mouse-adapted influenza b virus in a mouse model. / Prokopyeva, Elena; Kurskaya, Olga; Sobolev, Ivan et al.
In: Viruses, Vol. 12, No. 4, v12040470, 01.04.2020.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Experimental infection using mouse-adapted influenza b virus in a mouse model
AU - Prokopyeva, Elena
AU - Kurskaya, Olga
AU - Sobolev, Ivan
AU - Solomatina, Mariia
AU - Murashkina, Tatyana
AU - Suvorova, Anastasia
AU - Alekseev, Alexander
AU - Danilenko, Daria
AU - Komissarov, Andrey
AU - Fadeev, Artem
AU - Ramsay, Edward
AU - Shestopalov, Alexander
AU - Dygai, Alexander
AU - Sharshov, Kirill
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Every year, influenza B viruses (IBVs) contribute to annual illness, and infection can lead to serious respiratory disease among humans. More attention is needed in several areas, such as increasing virulence or pathogenicity of circulating B viruses and developing vaccines against current influenza. Since preclinical trials of anti-influenza drugs are mainly conducted in mice, we developed an appropriate infection model, using an antigenically-relevant IBV strain, for furtherance of anti-influenza drug testing and influenza vaccine protective efficacy analysis. A Victoria lineage (clade 1A) IBV was serially passaged 17 times in BALB/c mice, and adaptive amino acid substitutions were found in hemagglutinin (HA) (T214I) and neuraminidase (NA) (D432N). By electron microscopy, spherical and elliptical IBV forms were noted. Light microscopy showed that mouse-adapted IBVs caused influenza pneumonia on day 6 post inoculation. We evaluated the illness pathogenicity, viral load, and histopathological features of mouse-adapted IBVs and estimated anti-influenza drugs and vaccine efficiency in vitro and in vivo. Assessment of an investigational anti-influenza drug (oseltamivir ethoxysuccinate) and an influenza vaccine (Ultrix®, SPBNIIVS, Saint Petersburg, Russia) showed effectiveness against the mouse-adapted influenza B virus.
AB - Every year, influenza B viruses (IBVs) contribute to annual illness, and infection can lead to serious respiratory disease among humans. More attention is needed in several areas, such as increasing virulence or pathogenicity of circulating B viruses and developing vaccines against current influenza. Since preclinical trials of anti-influenza drugs are mainly conducted in mice, we developed an appropriate infection model, using an antigenically-relevant IBV strain, for furtherance of anti-influenza drug testing and influenza vaccine protective efficacy analysis. A Victoria lineage (clade 1A) IBV was serially passaged 17 times in BALB/c mice, and adaptive amino acid substitutions were found in hemagglutinin (HA) (T214I) and neuraminidase (NA) (D432N). By electron microscopy, spherical and elliptical IBV forms were noted. Light microscopy showed that mouse-adapted IBVs caused influenza pneumonia on day 6 post inoculation. We evaluated the illness pathogenicity, viral load, and histopathological features of mouse-adapted IBVs and estimated anti-influenza drugs and vaccine efficiency in vitro and in vivo. Assessment of an investigational anti-influenza drug (oseltamivir ethoxysuccinate) and an influenza vaccine (Ultrix®, SPBNIIVS, Saint Petersburg, Russia) showed effectiveness against the mouse-adapted influenza B virus.
KW - Amino acid substitutions
KW - Antiviral drugs
KW - Influenza B virus
KW - Influenza model
KW - Influenza vaccine
KW - Mouse-adapted
KW - Pathogenicity
KW - Virulence
KW - influenza vaccine
KW - amino acid substitutions
KW - antiviral drugs
KW - mouse-adapted
KW - influenza model
KW - NEURAMINIDASE
KW - pathogenicity
KW - virulence
KW - influenza B virus
KW - RESISTANCE
UR - http://www.scopus.com/inward/record.url?scp=85083838391&partnerID=8YFLogxK
U2 - 10.3390/v12040470
DO - 10.3390/v12040470
M3 - Article
C2 - 32326238
AN - SCOPUS:85083838391
VL - 12
JO - Viruses
JF - Viruses
SN - 1999-4915
IS - 4
M1 - v12040470
ER -
ID: 24092286